E16 FIP-WHO session: Points to consider in the provision by health care professionals of children-specific preparations that are not available as authorised products
Monday 29 August 2016
14:30-16:00
Hilton Buenos Aires : Pacara A & B, 1.5 hours
Organised by FIP and WHO
Introduction
Paediatric patients should have access to authorized, age-appropriate preparations of medicines that can be administered safely and effectively. However, it is recognized that such preparations are not always available and in such cases a safe and effective alternative must be sought. This session will introduce the topic of paediatric medicines and related issues in paediatric pharmacy practice. This session will introduce the new FIP-WHO guidance document that aims to serve as a practical document that addresses current needs for advice in the search for an alternative to an authorized, age-appropriate dosage form, mainly for paediatric medicines for oral administration. Although the guidance takes the form of a working practical document it is important to invite comment and input from interested practitioners so that the guidance can be developed further in response to feedback. At this session the audience will have the possibility to have a vivid discussion on this document and on the need for paediatric pharmacy practice supported by relevant evidence.
Learning objectives
At the conclusion of this knowledge-based session, participants will be able to:
- Identify the main issues in children-specific preparations and paediatric pharmacy practice
- Explain the need for guidance in the search for an alternative to an authorised, age-appropriate dosage form, mainly for paediatric medicines for oral administration
- Describe the value and benefits of the FIP-WHO guidelines
- Describe the role of WHO.
Chair
Sabine Kopp (WHO, Switzerland)
Programme
14:30
1) Introduction by the Chair
14:35
2) Challenges and needs in paediatric medicines and the role of global health institutions
Facundo Garcia Bournissen (The National Scientific and Technical Research Council - CONICET, Argentina)
14:55
3) Introduction of the FIP–WHO technical guidelines: Points to consider in the provision by health care professionals of children-specific preparations that are not available as authorised products
Sabine Kopp (WHO, Switzerland)
15:15
4) Paediatric pharmacy practice
Régis Vaillancourt (Children’s Hospital of Eastern Ontario, Canada)
15:35
5) Discussion and Q&A